Rejection of the kidney allograft

New England Journal of Medicine

Volumn 363, Issue 15, 2010, Pages 1451-1462

  Nankivell, Brian J ^a,c,d   Alexander, Stephen I ^b,c,d  

^a WESTMEAD HOSPITAL   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; BELATACEPT; BLOOD GROUP ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; OKT 3; THYMOCYTE ANTIBODY; ANTIBODY;

ACUTE GRAFT REJECTION; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; CELL MOTION; CHRONIC GRAFT REJECTION; EFFECTOR CELL; HYPERACUTE GRAFT REJECTION; IMMUNE SYSTEM; KIDNEY ALLOGRAFT; KIDNEY DONOR; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; ALLOTRANSPLANTATION; ARTERITIS; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; KIDNEY; KIDNEY TRANSPLANTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANTIBODIES; ARTERITIS; BLOOD GROUP ANTIGENS; GRAFT REJECTION; HUMANS; IMMUNITY, INNATE; ISOANTIGENS; KIDNEY; KIDNEY TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 77957734604     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra0902927     Document Type: Review

References (74)

1. Morris PJ. Transplantation - a medical miracle of the 20th century. N Engl J Med 2004;351:2678-80.
2. Sayegh MH, Carpenter CB. Transplantation 50 years later - progress, challenges, and promises. N Engl J Med 2004;351:2761-6.
3. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004;4:378-83 (Pubitemid 38282293)
4. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326-33.
5. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-29.
6. Sis B, Mengel M, Haas M, et al. Banff '09 Meeting Report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010;10:464-71.
7. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008;8:753-60.
8. Briscoe DM, Alexander SI, Lichtman AH. Interactions between T lymphocytes and endothelial cells in allograft rejection. Curr Opin Immunol 1998;10:525-31.
9. Kim IK, Bedi DS, Denecke C, Ge X, Tullius SG. Impact of innate and adaptive immunity on rejection and tolerance. Transplantation 2008;86:889-94.
10. Alegre ML, Leemans J, Le Moine A, et al. The multiple facets of toll-like receptors in transplantation biology. Transplantation 2008;86:1-9.
11. Brown KM, Kondeatis E, Vaughan RW, et al. Influence of donor C3 allotype on late renal-transplantation outcome. N Engl J Med 2006;354:2014-23.
12. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002;8:582-7.
13. Strainic MG, Liu J, Huang D, et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 2008;28:425-35.
14. Zhou W, Medof ME, Heeger PS, Sacks S. Graft-derived complement as a mediator of transplant injury. Curr Opin Immunol 2007;19:569-76.
15. Sumitran-Holgersson S. Relevance of MICA and other non-HLA antibodies in clinical transplantation. Curr Opin Immunol 2008;20:607-13.
16. Zou Y, Stastny P, Süsal C, Döhler B, Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007;357:1293-300 (Pubitemid 47481451)
17. Danovitch GM, Cecka JM. Allocation of deceased donor kidneys: past, present, and future. Am J Kidney Dis 2003;42:882-90.
18. Stratta RJ, Sundberg AK, Rohr MS, et al. Optimal use of older donors and recipients in kidney transplantation. Surgery 2006;139:324-33.
19. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995;333:333-6.
20. Lynch RJ, Platt JL. Accommodation in organ transplantation. Curr Opin Organ Transplant 2008;13:165-70.
21. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007;18:1046-56.
22. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003;3:665-73.
23. Dragun D, Müller DN, Bräsen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005;352:558-69.
24. Scornik JC, Guerra G, Schold JD, Srinivas TR, Dragun D, Meier-Kriesche HU. Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction. Am J Transplant 2007;7:1808-14 (Pubitemid 46905444)
25. Pescovitz MD. Rituximab, an anticd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006;6:859-66.
26. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008;359:242-51 (Pubitemid 352008439)
27. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009;9:231-5.
28. Stegall MD, Gloor JM. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant 2010;15:8-10.
29. Larsen CP, Morris PJ, Austyn JM. Migration of dendritic leukocytes from cardiac allografts into host spleens: a novel pathway for initiation of rejection. J Exp Med 1990;171:307-14.
30. Hagerty DT, Allen PM. Processing and presentation of self and foreign antigens by the renal proximal tubule. J Immunol 1992;148:2324-30.
31. Kreisel D, Krupnick AS, Balsara KR, et al. Mouse vascular endothelium activates CD8+ T lymphocytes in a B7-dependent fashion. J Immunol 2002;169:6154-61 (Pubitemid 36903460)
32. Baddoura FK, Nasr IW, Wrobel B, Li Q, Ruddle NH, Lakkis FG. Lymphoid neogenesis in murine cardiac allografts undergoing chronic rejection. Am J Transplant 2005;5:510-6 (Pubitemid 40313342)
33. Trowsdale J, Parham P. Mini-review: defense strategies and immunity-related genes. Eur J Immunol 2004;34:7-17 (Pubitemid 38111515)
34. Gudmundsdottir H, Turka LA. A closer look at homeostatic proliferation of CD4+ T cells: costimulatory requirements and role in memory formation. J Immunol 2001;167:3699-707.
35. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001;166:973-81.
36. Vella JP, Vos L, Carpenter CB, Sayegh MH. Role of indirect allorecognition in experimental late acute rejection. Transplantation 1997;64:1823-8.
37. Womer KL, Sayegh MH, Auchincloss H Jr. Involvement of the direct and indirect pathways of allorecognition in tolerance induction. Philos Trans R Soc Lond B Biol Sci 2001;356:639-47.
38. Ely LK, Burrows SR, Purcell AW, Rossjohn J, McCluskey J. T-cells behaving badly: structural insights into alloreactivity and autoimmunity. Curr Opin Immunol 2008;20:575-80.
39. Jiang S, Herrera O, Lechler RI. New spectrum of allorecognition pathways: implications for graft rejection and transplantation tolerance. Curr Opin Immunol 2004;16:550-7.
40. Chen Y, Wood KJ. Interleukin-23 and TH17 cells in transplantation immunity: does 23+17 equal rejection? Transplantation 2007;84:1071-4.
41. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009;361:888-98.
42. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003;3:199-210.
43. Zhai Y, Ghobrial RM, Busuttil RW, Kupiec-Weglinski JW. Th1 and Th2 cytokines in organ transplantation: paradigm lost? Crit Rev Immunol 1999;19:155-72.
44. Csencsits KL, Bishop DK. Contrasting alloreactive CD4+ and CD8+ T cells: there's more to it than MHC restriction. Am J Transplant 2003;3:107-15.
45. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005;353:2342-51.
46. Bunnag S, Allanach K, Jhangri GS, et al. FOXP3 expression in human kidney transplant biopsies is associated with rejection and time post transplant but not with favorable outcomes. Am J Transplant 2008;8:1423-33.
47. Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev 2009;229:271-93.
48. Dooms H, Abbas AK. Control of CD4+ T-cell memory by cytokines and costimulators. Immunol Rev 2006;211:23-38.
49. Mariat C, Degauque N, Strom TB. TIM-1: a new player in transplant immunity. Transplantation 2009;87:Suppl:S84-S86.
50. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353:770-81 (Pubitemid 41215486)
51. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004;4:1019-25 (Pubitemid 38868590)
52. Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007;7:1770-7 (Pubitemid 46905435)
53. Akalin E, Hendrix RC, Polavarapu RG, et al. Gene expression analysis in human renal allograft biopsy samples using highdensity oligoarray technology. Transplantation 2001;72:948-53 (Pubitemid 32879872)
54. Hoffmann SC, Hale DA, Kleiner DE, et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant 2005;5:573-81.
55. Cornell LD, Smith RN, Colvin RB. Kidney transplantation: mechanisms of rejection and acceptance. Annu Rev Pathol 2008;3:189-220.
56. Sarwal M, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003;349:125-38.
57. Wyburn KR, Jose MD, Wu H, Atkins RC, Chadban SJ. The role of macrophages in allograft rejection. Transplantation 2005;80:1641-7.
58. Robertson H, Morley AR, Talbot D, Callanan K, Kirby JA. Renal allograft rejection: beta-chemokine involvement in the development of tubulitis. Transplantation 2000;69:684-7.
59. Segerer S, Cui Y, Eitner F, et al. Expression of chemokines and chemokine receptors during human renal transplant rejection. Am J Kidney Dis 2001;37:518-31.
60. Barry M, Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol 2002;2:401-9 (Pubitemid 37328747)
61. Zorn E, Miklos DB, Floyd BH, et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med 2004;199:1133-42.
62. Al-Lamki RS, Wang J, Skepper JN, Thiru S, Pober JS, Bradley JR. Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants. Lab Invest 2001;81:1503-15.
63. Imagawa DK, Millis JM, Seu P, et al. The role of tumor necrosis factor in allograft rejection. III. Evidence that anti-TNF antibody therapy prolongs allograft survival in rats with acute rejection. Transplantation 1991;51:57-62.
64. Robertson H, Kirby JA. Post-transplant renal tubulitis: the recruitment, differentiation and persistence of intra-epithelial T cells. Am J Transplant 2003;3:3-10 (Pubitemid 36306816)
65. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009;119:1417-9.
66. Bonsib SM, Abul-Ezz SR, Ahmad I, et al. Acute rejection-associated tubular basement membrane defects and chronic allograft nephropathy. Kidney Int 2000;58:2206-14.
67. Middleton J, Patterson AM, Gardner L, Schmutz C, Ashton BA. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 2002;100:3853-60.
68. Sun Q, Liu ZH, Ji S, et al. Late and early C4d-positive acute rejection: different clinico-histopathological subentities in renal transplantation. Kidney Int 2006;70:377-83.
69. Anglicheau D, Suthanthiran M. Noninvasive prediction of organ graft rejection and outcome using gene expression patterns. Transplantation 2008;86:192-9.
70. Bestard O, Nickel P, Cruzado JM, et al. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol 2008;19:1419-29.
71. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006;82:663-8.
72. Hu H, Kwun J, Aizenstein BD, Knechtle SJ. Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine. Transplantation 2009;87:1814-20.
73. Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001;344:947-54.
74. Reeve J, Einecke G, Mengel M, et al. Diagnosing rejection in renal transplants: a comparison of molecular- and histopathology-based approaches. Am J Transplant 2009;9:1802-10.